National and international developments in cancer, health and policy. Produced in collaboration with the Press Association unless otherwise stated.
New clinical trial results show that adding rituximab to standard chemotherapy could improve survival for some children with non-Hodgkin lymphoma.
A new immunotherapy treatment has been recommended by the National Institute for Health and Care Excellence (NICE) for some adults with small cell lung cancer.
Atezolizumab used in combination with nab-paclitaxel is the first immunotherapy available for triple negative breast cancer.
A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer.